ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. Issue 9 (September 2020)

• Record Type: Journal Article
• Authors: Chen, Chi-Wei; Buj, Raquel; Dahl, Erika S.; Leon, Kelly E.; Aird, Katherine M.
• Is Part Of: Heliyon. Volume 6:Issue 9(2020)
• Publication Date: 2020-09
• Subjects: Cell biology -- Bioinformatics -- Metabolite -- Biochemistry -- Molecular biology -- Cancer research -- PPARa -- Cellular senescence -- Cellular metabolism -- Drug combinations -- Homologous recombination; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2020.e05097
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: While therapies targeting deficiencies in the homologous recombination (HR) pathway are emerging as the standard treatment for high grade serous ovarian cancer (HGSOC) patients, this strategy is limited to the ~50% of patients with a deficiency in this pathway. Therefore, patients with HR-proficient tumors are likely to be resistant to these therapies and require alternative strategies. We found that the HR gene Ataxia Telangiectasia Mutated (ATM) is wildtype and its activity is upregulated in HGSOC compared to normal fallopian tube tissue. Interestingly, multiple pathways related to metabolism are inversely correlated with ATM expression in HGSOC specimens, suggesting that combining ATM inhibition with metabolic drugs would be effective. Analysis of FDA-approved drugs from the Dependency Map demonstrated that ATM-low cells are more sensitive to fenofibrate, a PPARα agonist that affects multiple cellular metabolic pathways. Consistently, PPARα signaling is associated with ATM expression. We validated that combined inhibition of ATM and treatment with fenofibrate is synergistic in multiple HGSOC cell lines by inducing senescence. Together, our results suggest that metabolic changes induced by ATM inhibitors are a potential target for the treatment of HGSOC. Abstract : Cell biology; Bioinformatics; Metabolite; Biochemistry; Molecular biology; Cancer research; PPARa; Cellular senescence; Cellular metabolism; Drug combinations; Homologous recombination